Riskpilot← Back to searchSign inGet full accessAmicus Therapeutics ApS
APSActiveCVR 39359340Rådhuspladsen 16Wholesale of pharmaceutical and medical goods · NACE 4646Est. 20181 employees
Revenue 2024
DKK 2M
+15% vs 2023
EBITDA margin
5.4%
+12% vs 2023
Equity ratio
9.0%
Financial strength
Net profit 2024
DKK 16K
-68% vs 2023
| Revenue | DKK 2M | +15% |
| EBITDA | DKK 108K | +12% |
| Net profit | DKK 16K | -68% |
| Total assets | DKK 3,4M | +367% |
| Equity | DKK 310K | -13% |
| Employees | 1 | — |
Legal name
Amicus Therapeutics ApS
CVR number
39359340
Legal form
Anpartsselskab
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
23. februar 2018
Share capital
DKK 50.000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktør og et bestyrelsesmedlem i forening eller af den samlede bestyrelse.
Company purpose
Selskabets formål er at markedsføre, distribuere og sælge produkter og tjenesteydelser.
Address
Rådhuspladsen 16
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenue | 1.979 | 2.019 | 490 | 644 | 1.576 | 1.732 | 1.987 |
| Staff expenses | -1.885 | -1.905 | -457 | -607 | -1.492 | -1.636 | -1.879 |
| EBITDA | 94 | 114 | 33 | 37 | 84 | 96 | 108 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | 94 | 114 | 33 | 37 | 84 | 96 | 108 |
| Net financials | 0 | -3 | -5 | -12 | -14 | -29 | -87 |
| Profit before tax | 94 | 111 | 28 | 25 | 69 | 67 | 21 |
| Tax | 21 | 26 | 6 | 5 | 15 | 15 | 5 |
| Net profit | 74 | 84 | 22 | 19 | 54 | 52 | 16 |
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Total assets | 1.979 | 497 | 2.286 | 2.416 | 617 | 734 | 3.426 |
| Equity | 124 | 208 | 230 | 249 | 303 | 355 | 310 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 1.856 | 289 | 2.057 | 2.167 | 314 | 379 | 3.117 |
| Total debt | 1.856 | 289 | 2.057 | 2.167 | 314 | 379 | 3.117 |
EBITDA margin
5.4%
This company
15.8%
Market median
-66% vs market
20182024
Equity ratio
9.0%
This company
38.2%
Market median
-76% vs market
20182024
Return on equity
5.3%
This company
18.4%
Market median
-71% vs market
20182024
Net profit margin
0.8%
This company
8.1%
Market median
-90% vs market
20182024
Asset turnover
0.58×
This company
1.12×
Market median
-48% vs market
20182024
Debt / equity
10.07×
This company
0.62×
Market median
-1524% vs market
20182024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-02-23 – 2018-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
CA Management | Management | 2023 | — | — |
JK Management | Management | 2018 | — | — |
JE Management | Management | 2020 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2018 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2018 | — | — | |
| Chairman | 2024 | — | — | |
| Board of Directors | 2024 | — | — | |
| Chairman | 2024 | — | — | |
| Chairman | 2020 | — | — | |
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2018 | — | — | |
| Board of Directors | 2018 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 100.0% | 100.0% | 2018 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Amicus Therapeutics ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Charlotte Ann Galvin | Management | 0 companies |
| Johnny Krogh Hansen | Management | 0 companies |
| John Erik Mattias Bankel | Management | 0 companies |
| Simon Collins | Chairman | 0 companies |
| Nicole Ruth Reichman | Board of Directors | 0 companies |
| Jasvinder Sarkaria | Board of Directors | 0 companies |
| David Malcolm Lewis | Chairman | 0 companies |
| Jessica Alice Stephens-Brown | Board of Directors | 0 companies |
| Ana Rogovic | Chairman | 0 companies |
| Anita Jane Clifford | Chairman | 0 companies |
| Steven John Green | Board of Directors | 0 companies |
| Lori Mochan | Board of Directors | 0 companies |
| Detlef Wolff | Board of Directors | 0 companies |